Tesamorelin
Also known as: Egrifta
strong human dataWADA bannedFDA approved: HIV-associated lipodystrophy
Mechanism of Action
Tesamorelin is a synthetic growth-hormone-releasing hormone analog. It stimulates pituitary growth hormone secretion and downstream IGF-1 production, with human evidence in HIV-associated abdominal adiposity; the training engine should treat it as GH-axis/metabolic context, not as generic fat-loss magic.
Key Citations
- Metabolic effects of a growth hormone-releasing factor in patients with HIV.
The New England journal of medicine · 2007 · PMID 18057338
Published Dose Range
No published dosing data available.
Published Cycle Range
Short12 wks
Typical14 wks
Long24 wks
12-16 week minimum for body composition changes. Up to 6 months.
Administration
Routessubcutaneous
FrequencyDaily
Safety Profile
Contraindications
- • Monitor IGF-1 levels
- • Diabetes caution
Common side effects
- • Glucose intolerance risk
- • Edema
- • Joint pain
Serious risks
- • Glucose intolerance
Requires monitoring
- • IGF-1 levels
- • Blood glucose
Pregnancy / breastfeeding
No data — consult clinician
Common Misconceptions
- Maintains GH receptor sensitivity better than exogenous HGH
Commonly Stacked With
CJC-1295IpamorelinBPC-157TB-500MK-677GHK-CuIGF-1 LR3
Next Steps
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.